Alterity Therapeutics Limited logo

Alterity Therapeutics LimitedNASDAQ: ATHE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Australia

IPO:

29 September 2003

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$9.35 M
-78%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector
-52%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 44 min ago
$1.07+$0.02(+1.90%)

Dividend

No data over the past 3 years
No data over the past 3 years
$930.00 K$930.00 K
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ATHE Latest News

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
globenewswire.com12 November 2024 Sentiment: POSITIVE

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity's Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System.

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
globenewswire.com31 October 2024 Sentiment: POSITIVE

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025 Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System Atrophy Multiple data presentations at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) Appointed Abby Macnish Niven as Chief Financial Officer Cash balance on 30 September 2024 of A$9.28m MELBOURNE, Australia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2024 (Q1 FY25). “We are excited about what this fiscal year has to offer as we started by reporting promising data from our Phase 2 clinical trial in participants with advanced multiple system atrophy (MSA),” said, David Stamler, M.D.

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
globenewswire.com14 October 2024 Sentiment: POSITIVE

MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 October 2024 at 4:30 a.m. AEDT in Australia.

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
globenewswire.com11 October 2024 Sentiment: POSITIVE

MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA.

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com02 October 2024 Sentiment: POSITIVE

- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations were presented at the International Congress of Parkinson's Disease and Movement Disorders® (MDS). “We significantly raised the profile of Alterity and ATH434 at the MDS Congress with several data presentations, including a late breaking oral presentation on data from our ATH434-202 Phase 2 open-label clinical trial in Multiple System Atrophy (MSA),” said David Stamler, M.D.

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
globenewswire.com30 September 2024 Sentiment: POSITIVE

MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company's Chief Financial Officer (CFO), effective today.

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com23 September 2024 Sentiment: POSITIVE

- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations will be presented at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) taking place September 27 – October 1, 2024 in Philadelphia, PA.

Alterity Therapeutics to Present at MST Financial Webinar
globenewswire.com24 July 2024 Sentiment: POSITIVE

MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company's recent developments, including the recently announced interim data for the Phase 2 open-label study of ATH-434 (202).

Alterity (ATHE) Up on Interim Data From Advance MSA Study
zacks.com18 July 2024 Sentiment: POSITIVE

Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
globenewswire.com17 July 2024 Sentiment: POSITIVE

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive interim data from the ATH434-202 open-label Phase 2 clinical trial in patients with multiple system atrophy (MSA). ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain.

  • 1(current)

What type of business is Alterity Therapeutics Limited?

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

What sector is Alterity Therapeutics Limited in?

Alterity Therapeutics Limited is in the Healthcare sector

What industry is Alterity Therapeutics Limited in?

Alterity Therapeutics Limited is in the Biotechnology industry

What country is Alterity Therapeutics Limited from?

Alterity Therapeutics Limited is headquartered in Australia

When did Alterity Therapeutics Limited go public?

Alterity Therapeutics Limited initial public offering (IPO) was on 29 September 2003

What is Alterity Therapeutics Limited website?

https://alteritytherapeutics.com

Is Alterity Therapeutics Limited in the S&P 500?

No, Alterity Therapeutics Limited is not included in the S&P 500 index

Is Alterity Therapeutics Limited in the NASDAQ 100?

No, Alterity Therapeutics Limited is not included in the NASDAQ 100 index

Is Alterity Therapeutics Limited in the Dow Jones?

No, Alterity Therapeutics Limited is not included in the Dow Jones index

When was Alterity Therapeutics Limited the previous earnings report?

No data

When does Alterity Therapeutics Limited earnings report?

Next earnings report date is not announced yet